ST Pharm Co.,Ltd.
Financials
Valuation Metrics
ST Pharm Co.,Ltd.'s Market Cap is ₩1.8T. At end of 2025 it was ₩2.5T. Ranked #219 of 2,414 in KR market (top 9%), #47 of 1,633 on KOSDAQ (top 3%), #20 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.77T KRW | KR#219/2,414 Sec#20/231 |
| Revenue | 386.46B KRW | KR#734/2,414 Sec#34/231 |
| Net Income | 76.84B KRW | KR#306/2,414 Sec#22/231 |
| Total Assets | 848.03B KRW | KR#529/2,414 Sec#28/231 |
| Net Assets | 629.07B KRW | KR#423/2,414 Sec#28/231 |
| Employees | 1,328 | KR#198/2,414 Sec#12/231 |
| Value | ||
| P/E | 23.04x | KR#1,252/2,414 Sec#75/231 |
| P/B | 2.81x | KR#2,115/2,414 Sec#165/231 |
| PEG | 0.17x | KR#532/2,414 Sec#32/231 |
| P/S | 4.58x | KR#2,134/2,414 Sec#143/231 |
| EV/EBITDA | 25.26x | KR#1,152/2,414 Sec#69/231 |
| FCF Yield | -1.87% | KR—/2,414 Sec—/231 |
| Profitability | ||
| ROE | 12.21% | KR#462/2,414 Sec#32/231 |
| ROA | 9.06% | KR#340/2,414 Sec#26/231 |
| Op. Margin | 18.33% | KR#196/2,414 Sec#19/231 |
| Revenue Growth | 29.64% | KR#397/2,414 Sec#40/231 |
| Earnings Growth | 138.55% | KR#325/2,414 Sec#19/231 |
| Financial Health | ||
| Debt Ratio | 34.81% | KR#688/2,414 Sec#84/231 |
| Total Debt | 72.77B KRW | KR#848/2,414 Sec#57/231 |
| FCF | -33.08B KRW | KR#2,005/2,414 Sec#194/231 |
| Cash | 53.83B KRW | KR#705/2,414 Sec#39/231 |
| Current Ratio | 2.28x | KR#763/2,414 Sec#90/231 |
| Net Debt/EBITDA | 0.27x | KR#639/2,414 Sec#38/231 |
| Dividend | ||
| Div. Yield | 0.60% | KR#1,249/2,414 Sec#76/231 |
| Div. Growth | 0.00% | KR—/2,414 Sec—/231 |
| Performance | ||
| 1Y Return | -11.11% | KR#899/2,414 Sec#52/231 |
| 1M Return | -5.15% | KR#1,024/2,414 Sec#96/231 |
| From 52W High | -50.73% | KR#1,268/2,414 Sec#99/231 |
| 1Y MDD | -49.79% | KR#975/2,414 Sec#78/231 |
| Trading | ||
| Volume | 84,585 shares | KR#1,048/2,414 Sec#103/231 |
| Trading Value | 7.09B KRW | KR#309/2,414 Sec#22/231 |
| Foreign Own. | 12.61% | KR#392/2,414 Sec#29/231 |
| Per Share | ||
| EPS | 3,681 KRW | KR#289/2,414 Sec#19/231 |
| BPS | 30,133 KRW | KR#374/2,414 Sec#26/231 |
Company Info
ST Pharm was founded as UCHEM Co., Ltd. in 2008, then changed its name after an absorption merger with Samchully Pharmaceutical in 2010, subsequently joining the Dong-A Socio Group. Leveraging its expertise in small molecule new drugs, the company has expanded into oligonucleotide therapeutics CDMO. ST Pharm holds the world's third-largest production capacity, initiated production with the expansion of its second oligonucleotide plant in 2025, and provides a one-stop service system encompassing new drug development, CRO, and CDMO. It is headquartered in Siheung-si, Gyeonggi-do.